Kymera Therapeutics, Inc.
KYMR · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $39.2M | $47.1M | −16.7% |
| Operating income | −$349M | −$262M | −33.5% |
| Net income | −$311M | −$224M | −39.1% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Oct 29, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $0K | $2.80M | −100% |
| Operating income | −$147M | −$92.5M | −59.1% |
| Net income | −$132M | −$82.2M | −60.6% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Kymera's revenue in FY2025?
- $39.2M in FY2025 (Fiscal year ended Dec 31, 2025), −16.7% vs $47.1M a year earlier, per its 10-K filed Feb 2026.
- Was Kymera profitable in FY2025?
- No: net income was −$311M and operating income −$349M in FY2025.
- What was Kymera's revenue in Q3 2026?
- $0K (−100% vs a year earlier), per its Form 10-Q filed Oct 29, 2026.